BeiGene Greater China

BeiGene Greater China is owned by BeiGene.

BeiGene is one of the...

• Forbes Global 2000 (#1783).

BeiGene is a company listed under the stock ticker 6160 (HK).

BeiGene has a direct presence in 2 countries.

They are in:

• Biotechnology67%
• Pharmaceuticals33%

View the org chart displaying its 5 main executives

Most searched biographies at BeiGene Greater China

• Xiaobin Wu, President
• Eva Yin, Chief Commercial Officer
• Hongyu Qian, Vice President, Medical Affairs

Popular executive movements at BeiGene

• Thomas Malley, Non-Executive Independent Director, has left the company  (posted on January 24 2024).
• Olivier Brandicour has joined the company as Director  (posted on January 24 2024).

Create your alert
to follow the executive moves at BeiGene Greater China.

BeiGene has 2,290 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Delphia Therapeutics has just announced a $67 Million fundraising (posted on May 7 2024).
• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by BeiGene Greater China

Social media about BeiGene Greater China

• BeiGene Greater China on Wikipedia, Google News & Yahoo Finance
• BeiGene Greater China on LinkedIn, Twitter & YouTube

Contact by email its executives including Eva Yin

Call BeiGene Greater China at +86 105...

View the org chart

Register to receive your alert

Report an error